
Ur Metser, MD, FRCPC
-
- Site Director, Princess Margaret Cancer Centre
- Division Head, Molecular Imaging
Dr. Ur Metser is the Division Head of Molecular Imaging at the Joint Department of Medical Imaging (UHN, Sinai Health and Women’s College Hospital), Site Director of Medical Imaging at the Princess Margaret Cancer Centre and holds the position of Professor of Radiology, Department of Medical Imaging at the University of Toronto. He also chairs the Ontario Provincial Positron Emission Tomography Steering Committee at Cancer Care Ontario, responsible for the evidence-based introduction of PET in Ontario. He graduated from the Faculty of Medicine at the Technion (Haifa) and completed his residency training at the Sourasky Medical Center (affiliate of Tel Aviv University) and fellowship programs in abdominal imaging at the University of Toronto, and PET imaging at McMaster University.
After serving as staff radiologist at the Departments of Radiology and Nuclear
Medicine in Tel-Aviv, he joined the Joint Department of Medical Imaging in the
Divisions of Abdominal Imaging and Molecular Imaging. He is a fellow of the Royal College of Physicians (Canada) and an active member in multiple international professional societies including the Radiological Society of North America, and Society of Nuclear Medicine, amongst others. Dr. Metser has published over 150 manuscripts in peer-reviewed journals, as well as multiple review articles, book chapters and practice guidelines. He is also a reviewer for a few of the field’s leading medical journals and is on the editorial board of Journal of Computed Axial Tomography.
His main clinical and research interests focus on novel molecular imaging probes, theranostics, hybrid imaging (PET/CT and PET/MR) for tumour detection, characterization and assessment of response to therapy with functional imaging.
- 68Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients With Clinical, Imaging, and/or Biochemical Suspicion of a Neuroendocrine Tumor
CONCLUSIONS: 68Ga-DOTATATE PET/CT is positive in nearly 3 of 4 patients with morphological suspicion of a NET, with the highest yield in those with […]
- Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies
CONCLUSIONS: 18F-DCFPyL PET/MRI excluded nearly 30% of patients with low-/intermediate-risk PCa from FT, with a potential role in decreasing […]
- International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote […]
- Evaluation of MR anatomically-guided PET reconstruction using a convolutional neural network in PSMA patients
Background. Recently, approaches have utilized the superior anatomical information provided by magnetic resonance imaging (MRI) to guide the […]
- [18F]-FDG PET in anal canal cancer: a systematic review and meta-analysis
CONCLUSION: PET may be a useful tool for anal canal cancer therapy planning and provides valuable prognostic information.
- Diagnostic performance of whole-body [18F]FDG PET/MR in cancer M staging: A systematic review and meta-analysis
CONCLUSION: [^(18)F]FDG PET/MR was a highly accurate modality in M staging in the reported [^(18)F]FDG-avid malignancies. The results showed high […]
- Mesorectal nodal metastasis with seminal vesicle invasion in biochemically recurrent prostate cancer
CONCLUSIONS: In this study, 11.3% of PCa patients with biochemical failure had MLN metastasis on ^(18) F-DCFPyL-PET/CT. pT3b disease was associated […]
- [18F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry
The purpose of this study was to determine the impact of [^(18)F]FDG PET/CT on the initial staging, restaging, clinical management, and outcomes of […]
- Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial
CONCLUSIONS: PSMA and/or Choline PET/CT before sRT can potentially improve patient ADT management by directing clinicians towards more appropriate […]
- Oligometastasis in Prostate Cancer: Can We Learn from Those "Excluded" from a Phase 2 Trial?
We conducted and previously published a phase 2 trial of metastasis-directed therapy (MDT) in men with recurrence of prostate cancer at a low […]
- Lymphotropic Pattern of Prostate-specific Membrane Antigen-detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease
CONCLUSIONS: Presence of cribriform morphology on RP specimens of patients with biochemical failure after RP is associated with increased odds of […]
- Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer
CONCLUSION: In patients with LABC, PET-CT detected more distant metastases than conventional staging, and fewer PET-CT patients received combined […]
- Respiratory and cardiac motion correction in positron emission tomography using elastic motion approach for simultaneous abdomen and thorax positron emission tomography-magnetic resonance imaging
CONCLUSIONS: The eMOCO technique was successfully implemented in PET-MRI in a clinical setting and produced the lowest SD compared to gated and […]
- Combination of FDG PET/CT Radiomics and Clinical Parameters for Outcome Prediction in Patients with Hodgkin's Lymphoma
CONCLUSION: We evaluated the value of baseline clinical parameters as well as combined PET and CT radiomics in HL patients for survival and the […]
- Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database
Lung cancer remains the leading cancer-related death across North America. Imaging is fundamental. Recently, healthcare disparities came into […]
- Prognostic Value of Sarcopenia and Metabolic Parameters of 18F-FDG-PET/CT in Patients with Advanced Gastroesophageal Cancer
We investigated the prognostic value of sarcopenia measurements and metabolic parameters of primary tumors derived from ^(18)F-FDG-PET/CT among […]
- The role of [18F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer
CONCLUSION: The combined [^(18)F]-DCFPyL PET/MRI radiomic model was the best-performing model and outperformed the clinical model for pathological […]
- Standardized classification schemes in reporting oncologic PET/CT
The imaging report is essential for the communication between physicians in patient care. The information it contains must be clear, concise with […]
- 18F-FDG PET/MRI in Detection of Pulmonary Malignancies: A Systematic Review and Meta-Analysis
Background There have been conflicting results regarding fluorine 18-labeled fluorodeoxyglucose (^(18)F-FDG) PET/MRI diagnostic performance in lung […]
- CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics Modeling
We investigate whether computed tomography (CT) derived radiomics may correlate with driver gene mutations in patients with pancreatic ductal […]
- Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer
We investigated, whether 18[18F]-FDG PET/CT-derived radiomics combined with sarcopenia measurements improves survival prognostication among patients […]
- Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
CONCLUSION: Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with […]
- Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial
BACKGROUND: Detection of skeletal metastases in patients with prostate cancer or breast cancer remains a major clinical challenge. We aimed to […]
- 18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
CONCLUSION: Although ^(18)F-DCFPyL has higher specificity than CT in detecting advanced HGSOC tumor sites, it detects less disease sites than CT, […]
- A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer
CONCLUSIONS: Metformin decreased cervical tumor hypoxia in this trial that selected for patients with hypoxic tumor. See related commentary by Lyng […]
- Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
CONCLUSIONS: Half of patients treated with MDT for molecularly defined-only oligorecurrent prostate cancer exhibited a biochemical response. This […]
- Nasopharyngeal Carcinoma Radiomic Evaluation with Serial PET/CT: Exploring Features Predictive of Survival in Patients with Long-Term Follow-Up
CONCLUSIONS: This study with long-term follow up data on NPC suggests that mainly PET-derived radiomic features are predictive for OS but not PFS in […]
- Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis
CONCLUSION: This meta-analysis showed an overall high diagnostic performance for [^(18)F]-FDG PET/MR in detecting CRC lesions/metastases. Thus, this […]
- Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer
Background Data regarding 2-(3-{1-carboxy-5-[(6-[^(18)F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (^(18)F-DCFPyL) PET in […]
- Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis
Background There is limited consensus regarding the relative diagnostic performance of cardiac MRI and fluorodeoxyglucose (FDG) PET for cardiac […]